ProKidney Corp.
NASDAQ•PROK
CEO: Dr. Bruce Culleton M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-06-30
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Contact Information
2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC, 27103, United States
336-999-7028
Market Cap
$551.46M
P/E (TTM)
-3.1
24.5
Dividend Yield
--
52W High
$7.13
52W Low
$0.54
52W Range
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data